Advertisement
Document › Details
Bactevo Ltd.. (1/25/17). "Press Release: Bactevo Wins Innovate Award". Cambridge.
Region | United Kingdom (GB) | |
Organisation | Bactevo Ltd. | |
Today | Nanna Therapeutics Ltd. | |
Group | Astellas (Group) | |
Organisation 2 | Innovate UK | |
Group | United Kingdom (GB) (govt) | |
Product | antibiotic | |
Product 2 | business development (state/region) | |
Index term | Bactevo–United Kingdom (govt): grant, 201701 Biomedical Catalyst grant £1.5m from Innovate UK | |
Person | Williams, David (Nanna Therapeutics 202004 CEO before Discuva) | |
Bactevo, the revolutionary Cambridge, UK-based drug discovery company has received an Innovate Award for a prestigious £1.5M grant. Exploiting revolutionary work in the field of integrated, accelerated drug discovery in micro-droplets, Bactevo will progress its programmes focused on generating new antibiotic drugs to highly drug resistant Gram-negative pathogens causing septicaemia, chest and serious urinary tract infections. The Biomedical Catalyst early-stage award is run by the UK’s innovation agency, Innovate UK, recognising Britain’s most innovative, cutting-edge young companies.
David Williams, Bactevo CEO said: “We are pleased to receive this prestigious recognition with a major award from Innovate UK, which will allow us to make a substantial contribution to reducing bacterial infection, currently having a profound effect on our healthcare systems. This is the first announcement on our therapeutic strategy and we will continue to add news on other active disease in due course, as we apply our revolutionary technology platform in other areas of unmet medical need.”
About Bactevo
Bactevo is a Cambridge, UK-based drug discovery company focused on providing new and transformative medicines for poorly addressed or untreatable diseases. Key to Bactevo’s success are a core set of proprietary technologies which give rapid and almost infinite chemistry capabilities and the ability to find leads using small amounts of patient-derived cells or tissue. These technologies use patented intellectual property in ultra-high throughput microfluidic synthetic chemistry, microbiome-derived small molecules, microfluidic screening and machine learning to increase the productivity of drug discovery by 1000-fold. Bactevo believes these capabilities will ultimately result in quicker cheaper and more effective drugs for patients.
For further information please contact:
David Williams, Chief Executive Officer
Email: info@bactevo.com
Tel: +44(0)1223 423506
About Innovate UK
Innovate UK is the UK’s innovation agency. It works with people, companies and partner organisations to find and drive the science and technology innovations that will grow the UK economy. For further information visit http://www.innovateuk.gov.uk.
Record changed: 2023-06-05 |
Advertisement
More documents for Astellas (Group)
- [1] Mogrify Ltd.. (10/2/23). "Press Release: Mogrify Extends Series A Financing to $46 Million USD". Cambridge....
- [2] Novartis AG. (1/24/23). "Press Release: Sandoz Announces Agreement to Acquire Leading Antifungal Agent Mycamine from Astellas, Reinforcing Hospital Offering and Leading Anti-infectives Portfolio". Basel....
- [3] Mogrify Ltd.. (7/5/22). "Press Release: Mogrify and Astellas Announce Collaboration to Conduct Research on in vivo Regenerative Medicine Approaches to Address Sensorineural Hearing Loss". Cambridge & Tokyo....
- [4] T-Knife Therapeutics, Inc.. (7/12/21). "Press Release: T-Knife Therapeutics Announces the Appointment of Megan Baierlein as Chief Operating Officer". San Francisco, CA & Berlin....
- [5] T-Knife GmbH. (1/19/21). "Press Release: T-Knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer". San Francisco, CA & Berlin....
- [6] Amolyt Pharma SAS. (6/8/20). "Press Release: Amolyt Pharma Appoints Pierre Legault as a Director and Chairman of its Board of Directors as Company Transitions into Clinical Stage". Lyon & Newton, MA....
- [7] Nanna Therapeutics Ltd.. (4/21/20). "Press Release: Astellas Announces Acquisition of Nanna". Tokyo & Cambridge....
- [8] Adaptimmune Therapeutics plc. (1/14/20). "Press Release: Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies". Tokyo, Philadelphia, PA & Oxfordshire....
- [9] Audentes Therapeutics, Inc.. (12/2/19). "Press Release: Astellas Enters into Definitive Agreement to Acquire Audentes Therapeutics". Tokyo & San Francisco, CA....
- [10] Astellas Pharma Inc.. (11/22/18). "Press Release: Astellas Executes License Agreement with an Option to Acquire JVS-100 Gene Therapy Program from Juventas". Tokyo & Cleveland, OH....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top